Inclusion Criteria:  Age ≥18 years as of study index date; the study index date is date of initiation of treatment with dapagliflozin Patient received/receiving treatment with dapagliflozin for HFrEF (EF ≤40%) in accordance with the local dapagliflozin product label Signed and dated informed consent prior to enrolment in the study  Exclusion Criteria:  Patient is enrolled less than 14 days or more than 60 days following initiation of dapagliflozin Prior treatment with dapagliflozin or other SGLT2i treatment Initiation of dapagliflozin outside of local HF label Diagnosis of Type 1 diabetes prior to enrolment